Pathway to Ascertain the Role of Pharmacogenomics in Healthcare Utilization Outcomes [Letter]

Abstract

Youssef M Roman Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, 23298, USACorrespondence: Youssef M RomanDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, 23298, USAEmail [email protected] I read with great interest and excitement the findings published in your journal by Takahashi1 and colleagues investigating the association between select pharmacogenetic variants and hospitalization and emergency department (ED) visits. However, I would like to share some comments regarding the study that have not been addressed in the original manuscript.   View the original paper by Takahashi and colleagues

Keywords

• adverse drug events
• pharmacogenomics
• healthcare utilization outcomes
• propensity scores